BJBabak Javid

Babak Javid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Babak Javid has a total of 230 co-authors. Here are the top co-authors by number of shared publications:

  • Yu-Xiang Chen

    Division of Experimental Medicine, University of California, San Francisco

    8 shared publications
  • Hao Li

    National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China

    7 shared publications
  • Jun-Hao Zhu

    Centre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China

    7 shared publications
  • Hemant Joshi

    University of California San Francisco

    6 shared publications
  • Miaomiao Pan

    School of Medicine, Tsinghua University

    6 shared publications
  • Hairong Huang

    National Clinical Laboratory on Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, P.R. China

    5 shared publications

Latest Publications

  • Open Access

    A small molecule increases mycobacterial translation fidelity without a fitness cost by targeting ribosomal protein S5

    by Jie Wu, Swarnava Chaudhuri, Sarah Caldwell Feid, Hemant Joshi, Miaomiao Pan, Qingwen Kawaji, Gang Liu, Babak Javid

    A central dogma of molecular biology is the “speed-accuracy trade-off,” where ribosomes must slow down to ensure accurate protein synthesis. In mycobacteria, a high basal level of mistranslation at glutamine and asparagine codons, caused by an indirect tRNA aminoacylation pathway, promotes tolerance to the antibiotic rifampicin. While pharmacologically increasing translational fidelity is a promising strategy to combat antibiotic tolerance, the underlying mechanisms remain poorly understood. Here, we screened 9,000 synthetic compounds and identified benzo[d]isoxazole-4,7-diones as a novel chemical class that reduces mycobacterial mistranslation. Medicinal chemistry optimization yielded a lead compound, 9787, with superior potency in decreasing mistranslation and reversing rifampicin tolerance. Using competitive chemical proteomics, we identified the 30S ribosomal protein S5 (RpS5) as the specific cellular target. Remarkably, compound 9787 enhances translational fidelity at concentrations that do not measurably impact the overall rate of protein synthesis. Our findings challenge the universality of the speed-accuracy trade-off, demonstrating that fidelity can be improved independently of translation speed. This work reveals that the ribosomal small subunit is a druggable target for modulating translational quality control, and introduces a new strategy for combating antibiotic-tolerant bacteria without the associated fitness cost of slowed translation. IMPORTANCE: A fundamental principle in molecular biology holds that ribosomes face a trade-off between translation speed and accuracy: going faster means making more errors, while maintaining high fidelity requires slowing down. This study challenges that paradigm by identifying a small molecule that increases translational accuracy in mycobacteria without affecting the rate of protein synthesis. The compound targets ribosomal protein S5 and specifically reduces errors arising from physiologically mischarged tRNAs—a quality control problem distinct from the well-studied codon-anticodon mismatches. This form of mistranslation contributes to antibiotic tolerance in tuberculosis, making it a potential therapeutic target. Our findings reveal unexpected flexibility in how ribosomes maintain translation quality and suggest that pharmacologically increasing fidelity without the fitness cost of slowed protein synthesis may be an attractive strategy for combating antibiotic-tolerant bacteria.

  • Open Access

    Ribosomal RNA methylation by GidB modulates discrimination of mischarged tRNA

    by Zhuo Bi, Yu-Xiang Chen, Iris D Young, Mohamad T Dandan, Hemant Joshi, Hong-Wei Su, Yuemeng Chen, Jiayao Hong, James S Fraser, Babak Javid

    Despite redundant cellular pathways to minimize translational errors, errors in protein synthesis are common. Pathways and mechanisms to minimize errors are classified as pre-ribosomal or ribosomal. Pre-ribosomal pathways are primarily concerned with the appropriate charging of tRNAs with their cognate amino acids. By contrast, the ribosomal decoding center is considered ‘blind’ to mischarged tRNAs since these have cognate codon•anti-codon pairing. Here, we identified that in mycobacteria, deletion of the 16S ribosomal RNA methyltransferase gidB led to increased ribosomal discrimination of mischarged tRNAs. Discrimination only occurred in mycobacteria enriched from environments or genetic backgrounds with high rates of mistranslation. GidB deletion was necessary, but not sufficient for reducing mistranslation due to misacylation. Analysis of new cryo-EM structures of the M. smegmatis ribosomes derived from wild-type and gidB -deleted strains point to the interaction between the base methylated by GidB on the 16S RNA and an asparagine on the ribosomal S12 protein that, when mistranslated to aspartate, may be involved in altering translational fidelity. Our data suggest a mechanism by which mycobacterial ribosomes can discriminate mischarged tRNAs and that 16S rRNA differential methylation by GidB may act to prevent catastrophic translational error.

  • Survival of the driest

    by Hemant Joshi, Babak Javid

  • Open Access

    Ribosomal RNA methylation by GidB modulates discrimination of mischarged tRNA

    by Zhuo Bi, Yu-Xiang Chen, Iris D Young, Mohamad T Dandan, Hemant Joshi, Hong-Wei Su, Yuemeng Chen, Jia-Yao Hong, James S Fraser, Babak Javid

    Despite redundant cellular pathways to minimize translational errors, errors in protein synthesis are common. Pathways and mechanisms to minimize errors are classified as pre-ribosomal or ribosomal. Pre-ribosomal pathways are primarily concerned with the appropriate charging of tRNAs with their cognate amino acid. By contrast, the ribosomal decoding centre is considered ‘blind’ to mischarged tRNAs since these have cognate codon•anti-codon pairing. Here, we identified that in mycobacteria, deletion of the 16S ribosomal RNA methyltransferase gidB led to increased ribosomal discrimination of mischarged tRNAs. Discrimination only occurred in mycobacteria enriched from environments or genetic backgrounds with high rates of mistranslation. GidB deletion was necessary but not sufficient for reducing mistranslation due to misacylation. Analysis of new cryoEM structures of the M. smegmatis ribosomes derived from wild-type and gidB-deleted strains point to the interaction between the base methylated by GidB on the 16S RNA and an asparagine on the ribosomal S12 protein that when mistranslated to aspartate may be involved in altering translational fidelity. Our data suggest a mechanism by which mycobacterial ribosomes can discriminate mischarged tRNAs and that 16S rRNA differential methylation by GidB may act to prevent catastrophic translational error.

  • A monovalent SMAC mimetic as a potential host-directed therapy for tuberculosis

    by Jiahong Ji, Xiaoyi Jiang, Xinlei Liao, Fengjiao Du, Guirong Wang, Hairong Huang, Miao Mei, Yuan He, Xu Tan, Babak Javid, et al.

    Background: Tuberculosis (TB) caused by the Mycobacterium tuberculosis complex (MTBC) is the leading cause of death from a single infectious agent worldwide. Current antibiotics fail against drug-resistant strains, highlighting the urgent need for novel therapies. Host-directed therapy (HDT), which enhances host immunity rather than targeting pathogens directly, offers a promising solution. Methods: In this study, we use the in vitro cells infection assays and in vivo mouse infection model to identify the effects of a monovalent second mitochondria-derived activator of caspases (SMAC) mimetic named BI82 against mycobacterial infections. Results: Here, we demonstrate that BI82 potently inhibits M. bovis growth in Raw264.7 macrophages, bone marrow-derived macrophages, and peripheral blood mononuclear cells, while exhibiting synergy with rifampicin. BI82 also significantly restricts M. tuberculosis growth in ex vivo whole-blood assays from both tuberculosis patients and healthy donors. Mechanistically, BI82 degrades cellular inhibitor of apoptosis protein 1 (cIAP1), promoting infected cell apoptosis as evidenced by elevated cleaved caspase-3 and phosphorylated MLKL levels. Caspase inhibition abrogates BI82's anti-mycobacterial effects, confirming apoptosis as the primary therapeutic pathway. In a mouse model, oral BI82 treatment degraded cIAP1, reduced M. bovis burden in lungs and spleens, alleviated lung lesions, and increased CD3⁺ T cells with elevated CD4/CD8 ratios. Notably, different SMAC mimetics showed pathogen-specific efficacy profiles, with monovalent compounds (BI82, LCL161) demonstrating superior activity compared to bivalent Birinapant against M. bovis. Conclusions: This study highlights BI82's unique apoptosis-dependent mechanism and broad-spectrum potential against mycobacterial infections, including drug-resistant TB, positioning it as a promising HDT candidate.


  • Open Access

    Early Antibody-Mediated Immunity to Tuberculosis in Mice Requires NLRP3

    by Rania Bouzeyen, Nyaradzai Sithole, Avia Watson, Lilach Abramovitz, Katya Rakayev, Adam Fillion, Tessa Dickson, Paul A. MacAry, Patricia A. Darrah, Robert A. Seder, et al.

    While antibodies have emerged as potential mediators of protective immunity against Mycobacterium tuberculosis (Mtb), their mechanisms of action remain incompletely understood. Here, we demonstrate that immune complexes of Mtb and monoclonal antibodies targeting the Mtb phosphate transporter subunit PstS1 robustly activate the NLRP3 inflammasome in human and murine macrophages, leading to enhanced interleukin-1β secretion. Surprisingly, antibody-mediated inflammasome activation occurred independently of cell-surface Fcγ receptors, as confirmed using Fc-domain glycosylation mutant mAbs and macrophages from Fcγ receptor-deficient mice. Crucially, NLRP3 is indispensable for early antibody-mediated protection in vivo, as both pharmacological inhibition, and genetic deletion of NLRP3 completely abolished protective effects of PstS1-specific antibodies in Mtb-infected mice. This mechanism extends beyond monoclonal antibodies, as polyclonal sera from intravenously BCG-immunized rhesus macaques also required NLRP3 for protective efficacy. Our findings reveal a previously unrecognized mechanism by which Mtb-specific antibodies enhance host defense through inflammasome activation, potentially informing novel approaches for tuberculosis vaccine development.


  • Open Access

    A small molecule increases mycobacterial translation fidelity without a fitness cost by targeting ribosomal protein S5

    by Jie Wu, Swarnava Chaudhuri, Sarah Caldwell Feid, Hemant Joshi, Miaomiao Pan, Qingwen Kawaji, Gang Liu, Babak Javid

    A central dogma of molecular biology is the "speed-accuracy trade-off," where ribosomes must slow down to ensure accurate protein synthesis. In mycobacteria, a high basal level of mistranslation at glutamine and asparagine codons, caused by an indirect tRNA aminoacylation pathway, promotes tolerance to the antibiotic rifampicin. While pharmacologically increasing translational fidelity is a promising strategy to combat antibiotic tolerance, the underlying mechanisms remain poorly understood. Here, we screened 9,000 synthetic compounds and identified benzo[d]isoxazole-4,7-diones as a novel chemical class that reduces mycobacterial mistranslation. Medicinal chemistry optimization yielded a lead compound, 9787 , with superior potency in decreasing mistranslation and reversing rifampicin tolerance. Using competitive chemical proteomics, we identified the 30S ribosomal protein S5 (RpS5) as the specific cellular target. Remarkably, compound 9787 enhances translational fidelity at concentrations that do not measurably impact the overall rate of protein synthesis. Our findings challenge the universality of the speed-accuracy trade-off, demonstrating that fidelity can be improved independently of translation speed. This work reveals that the ribosomal small subunit is a druggable target for modulating translational quality control and introduces a new strategy for combating antibiotic-tolerant bacteria without the associated fitness cost of slowed translation. Importance: A fundamental principle in molecular biology holds that ribosomes face a trade-off between translation speed and accuracy: going faster means making more errors, while maintaining high fidelity requires slowing down. This study challenges that paradigm by identifying a small molecule that increases translational accuracy in mycobacteria without affecting the rate of protein synthesis. The compound targets ribosomal protein S5 and specifically reduce errors arising from physiologically mischarged tRNAs – a quality control problem distinct from the well-studied codon•anticodon mismatches. This form of mistranslation contributes to antibiotic tolerance in tuberculosis, making it a potential therapeutic target. Our findings reveal unexpected flexibility in how ribosomes maintain translation quality and suggest that pharmacologically increasing fidelity without the fitness cost of slowed protein synthesis may be an attractive strategy for combating antibiotic-tolerant bacteria.

  • Open Access

    Mechanical morphotype switching as an adaptive response in mycobacteria

    by Haig Alexander Eskandarian, Yu-Xiang Chen, Chiara Toniolo, Juan M. Belardinelli, Zuzana Palcekova, Lesley Hom, Paul D. Ashby, Georg E. Fantner, Mary Jackson, John D. McKinney, et al.

    Invading microbes face a myriad of cidal mechanisms of phagocytes that inflict physical damage to microbial structures. How intracellular bacterial pathogens adapt to these stresses is not fully understood. Here, we report the discovery of a virulence mechanism by which changes to the mechanical stiffness of the mycobacterial cell surface confer refraction to killing during infection. Long-term time-lapse atomic force microscopy was used to reveal a process of “mechanical morphotype switching” in mycobacteria exposed to host intracellular stress. A “soft” mechanical morphotype switch enhances tolerance to intracellular macrophage stress, including cathelicidin. Both pharmacologic treatment, with bedaquiline, and a genetic mutant lacking uvrA modified the basal mechanical state of mycobacteria into a soft mechanical morphotype, enhancing survival in macrophages. Our study proposes microbial cell mechanical adaptation as a critical axis for surviving host-mediated stressors.


  • Open Access

    Author Correction: An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis

    by Shivankari Krishnananthasivam, Hao Li, Rania Bouzeyen, Bhuvaneshwari Shunmuganathan, Kiren Purushotorman, Xinlei Liao, Fengjiao Du, Claudia Guldager Kring Friis, Felicity Crawshay-Williams, Low Heng Boon, et al.


  • Open Access

    An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis

    by Shivankari Krishnananthasivam, Hao Li, Rania Bouzeyen, Bhuvaneshwari Shunmuganathan, Kiren Purushotorman, Xinlei Liao, Fengjiao Du, Claudia Guldager Kring Friis, Felicity Crawshay-Williams, Low Heng Boon, et al.

    Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (Mtb). Whilst a functional role for humoral immunity in Mtb protection remains poorly defined, previous studies have suggested that antibodies can contribute towards host defense. Thus, identifying the critical components in the antibody repertoires from immune, chronically exposed, healthy individuals represents an approach for identifying new determinants for natural protection. In this study, we performed a thorough analysis of the IgG/IgA memory B cell repertoire from occupationally exposed, immune volunteers. We detail the identification and selection of a human monoclonal antibody that exhibits protective activity in vivo and show that it targets a virulence factor LpqH. Intriguingly, protection in both human ex vivo and murine challenge experiments was isotype dependent, with most robust protection being mediated via IgG2 and IgA. These data have important implications for our understanding of natural mucosal immunity for Mtb and highlight a new target for future vaccine development.